Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in Spain
Abstract Introduction Insulin lispro 100 units/mL Jr KwikPen is the first prefilled, disposable, half‐unit insulin pen that delivers 0.5–30 units in increments of 0.5 units for the treatment of patients with diabetes. This study describes the profile of patients in Spain who initiated insulin therap...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Endocrinology, Diabetes & Metabolism |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/edm2.451 |
| _version_ | 1827765036000477184 |
|---|---|
| author | F. Javier Ampudia‐Blasco Natalia Duque Esther Artime Elena Caveda Erik Spaepen Silvia Díaz‐Cerezo Miriam Rubio‐ deSantos Daniel Callejo Velasco M. Pilar Bahíllo‐Curieses |
| author_facet | F. Javier Ampudia‐Blasco Natalia Duque Esther Artime Elena Caveda Erik Spaepen Silvia Díaz‐Cerezo Miriam Rubio‐ deSantos Daniel Callejo Velasco M. Pilar Bahíllo‐Curieses |
| author_sort | F. Javier Ampudia‐Blasco |
| collection | DOAJ |
| description | Abstract Introduction Insulin lispro 100 units/mL Jr KwikPen is the first prefilled, disposable, half‐unit insulin pen that delivers 0.5–30 units in increments of 0.5 units for the treatment of patients with diabetes. This study describes the profile of patients in Spain who initiated insulin therapy with Jr KwikPen in a real‐world setting. Methods This retrospective, observational study based on IQVIA's electronic medical records database included patients with Type 1 (T1D) or Type 2 (T2D) diabetes who initiated therapy with Jr KwikPen between May 2018 and December 2020. Sociodemographic, clinical, and treatment characteristics at treatment initiation were analysed descriptively. Results A total of 416 patients were included. The main characteristics of the T1D/T2D groups (N = 326/90), respectively were as follows: female sex, 61.7%/65.6%; mean age (standard deviation [SD]), 32.5 (20.7)/55.5 (16.6) years; body mass index, 20.9 (4.2)/25.2 (4.6) kg/m2 (N = 239/77); HbA1c, 7.8 (1.7)%/8.0 (1.5)% (N = 141/64); and presence of diabetes‐associated comorbidities, 27.9%/64.4%. Only 32.8% of patients with T1D were < 18 years old. Among Jr KwikPen users, 12.3% (T1D/T2D, 7.7%/28.9%) were ≥ 65 years old, 17.1% patients were newly diagnosed, and 3.8% were pregnant women. The mean (SD) total insulin dose pre‐index for T1D/T2D was 43.1 (23.6) and 40.7 (21.6) UI/day, respectively. The mean (SD) insulin dose at the start of Jr KwikPen use was 26.63 (16.56) and 22.58 (13.59) UI/day for T1D/T2D, respectively. Jr KwikPen was first prescribed mainly by endocrinologists (58.7%) or paediatricians (22.6%). Conclusions The profile of patients who initiated therapy with Jr KwikPen in routine practice was broad with many patients being adults. Most of these patients had T1D, inadequate glycemic control, and multiple associated comorbidities. These results suggest that Jr KwikPen is prescribed in patients who may benefit from finer insulin dose adjustments, namely children, adolescents, adults, older individuals, or pregnant women with T1D or T2D. |
| first_indexed | 2024-03-11T11:13:23Z |
| format | Article |
| id | doaj.art-587b8576001746fc970ed5717d556853 |
| institution | Directory Open Access Journal |
| issn | 2398-9238 |
| language | English |
| last_indexed | 2024-03-11T11:13:23Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Endocrinology, Diabetes & Metabolism |
| spelling | doaj.art-587b8576001746fc970ed5717d5568532023-11-11T09:37:05ZengWileyEndocrinology, Diabetes & Metabolism2398-92382023-11-0166n/an/a10.1002/edm2.451Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in SpainF. Javier Ampudia‐Blasco0Natalia Duque1Esther Artime2Elena Caveda3Erik Spaepen4Silvia Díaz‐Cerezo5Miriam Rubio‐ deSantos6Daniel Callejo Velasco7M. Pilar Bahíllo‐Curieses8Endocrinology and Nutrition Department Clinic University Hospital Valencia, INCLIVA Research Foundation Valencia SpainEli Lilly and Company Madrid SpainEli Lilly and Company Madrid SpainEli Lilly and Company Madrid SpainHaaPACS GmbH Schriesheim GermanyEli Lilly and Company Madrid SpainEli Lilly and Company Madrid SpainIQVIA Madrid SpainServicio de Pediatría, Endocrinología Pediátrica, Hospital Clínico Universitario de Valladolid Valladolid SpainAbstract Introduction Insulin lispro 100 units/mL Jr KwikPen is the first prefilled, disposable, half‐unit insulin pen that delivers 0.5–30 units in increments of 0.5 units for the treatment of patients with diabetes. This study describes the profile of patients in Spain who initiated insulin therapy with Jr KwikPen in a real‐world setting. Methods This retrospective, observational study based on IQVIA's electronic medical records database included patients with Type 1 (T1D) or Type 2 (T2D) diabetes who initiated therapy with Jr KwikPen between May 2018 and December 2020. Sociodemographic, clinical, and treatment characteristics at treatment initiation were analysed descriptively. Results A total of 416 patients were included. The main characteristics of the T1D/T2D groups (N = 326/90), respectively were as follows: female sex, 61.7%/65.6%; mean age (standard deviation [SD]), 32.5 (20.7)/55.5 (16.6) years; body mass index, 20.9 (4.2)/25.2 (4.6) kg/m2 (N = 239/77); HbA1c, 7.8 (1.7)%/8.0 (1.5)% (N = 141/64); and presence of diabetes‐associated comorbidities, 27.9%/64.4%. Only 32.8% of patients with T1D were < 18 years old. Among Jr KwikPen users, 12.3% (T1D/T2D, 7.7%/28.9%) were ≥ 65 years old, 17.1% patients were newly diagnosed, and 3.8% were pregnant women. The mean (SD) total insulin dose pre‐index for T1D/T2D was 43.1 (23.6) and 40.7 (21.6) UI/day, respectively. The mean (SD) insulin dose at the start of Jr KwikPen use was 26.63 (16.56) and 22.58 (13.59) UI/day for T1D/T2D, respectively. Jr KwikPen was first prescribed mainly by endocrinologists (58.7%) or paediatricians (22.6%). Conclusions The profile of patients who initiated therapy with Jr KwikPen in routine practice was broad with many patients being adults. Most of these patients had T1D, inadequate glycemic control, and multiple associated comorbidities. These results suggest that Jr KwikPen is prescribed in patients who may benefit from finer insulin dose adjustments, namely children, adolescents, adults, older individuals, or pregnant women with T1D or T2D.https://doi.org/10.1002/edm2.451diabetes mellitus, Type 1diabetes mellitus, Type 2insulin lisproretrospective study |
| spellingShingle | F. Javier Ampudia‐Blasco Natalia Duque Esther Artime Elena Caveda Erik Spaepen Silvia Díaz‐Cerezo Miriam Rubio‐ deSantos Daniel Callejo Velasco M. Pilar Bahíllo‐Curieses Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in Spain Endocrinology, Diabetes & Metabolism diabetes mellitus, Type 1 diabetes mellitus, Type 2 insulin lispro retrospective study |
| title | Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in Spain |
| title_full | Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in Spain |
| title_fullStr | Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in Spain |
| title_full_unstemmed | Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in Spain |
| title_short | Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in Spain |
| title_sort | which people with diabetes are treated with a disposable half unit insulin pen a real world retrospective database study in spain |
| topic | diabetes mellitus, Type 1 diabetes mellitus, Type 2 insulin lispro retrospective study |
| url | https://doi.org/10.1002/edm2.451 |
| work_keys_str_mv | AT fjavierampudiablasco whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain AT nataliaduque whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain AT estherartime whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain AT elenacaveda whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain AT erikspaepen whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain AT silviadiazcerezo whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain AT miriamrubiodesantos whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain AT danielcallejovelasco whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain AT mpilarbahillocurieses whichpeoplewithdiabetesaretreatedwithadisposablehalfunitinsulinpenarealworldretrospectivedatabasestudyinspain |